利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.017 秒)

    METHOD AND OPHTHALMIC DEVICE FOR GALVANIC HEALING OF AN EYE
    5.
    发明申请
    METHOD AND OPHTHALMIC DEVICE FOR GALVANIC HEALING OF AN EYE 有权
    眼科手术治疗方法与眼科手术

    公开(公告)号：US20140005514A1

    公开(公告)日：2014-01-02

    申请号：US13928689

    申请日：2013-06-27

    申请人： Johnson & Johnson Vision Care, Inc.

    发明人： Randall Pugh ,  Annabelle Gallois-Bernos ,  Adam Toner ,  Andres Arrubla

    IPC分类号： A61F9/00 ,  A61B3/10 ,  A61N1/04

    CPC分类号： A61F9/0017 ,  A61B3/10 ,  A61N1/0448 ,  A61N1/0468 ,  A61N1/205 ,  A61N1/306 ,  A61N1/325 ,  A61N1/326 ,  A61N1/36046 ,  G02B1/043

    摘要： An apparatus for controlled healing of ocular erosions is described. The apparatus comprising; an optical surface comprising an energizable controller capable of being programmed to transmit energy from an energy source onto/into an ocular surface, through the use of a current generator in electrical connection with energy emitting contacts capable of transmitting an electric field. The controller, current generator and energy emitting contacts are biocompatible or encapsulated by a conductive biocompatible layer to allow positioning of said apparatus in an ocular surface.

    摘要翻译： 描述了一种用于控制眼部糜烂愈合的装置。 该装置包括： 光学表面包括能够被编程以通过使用与能够发射电场的能量发射触点电连接的电流发生器将能量从能量源传输到眼表面上的能量控制器。 控制器，电流发生器和能量发射触点是生物相容的或由导电生物相容层封装，以允许将所述装置定位在眼表面上。

    Esters for treatment of ocular inflammatory conditions
    6.
    发明授权
    Esters for treatment of ocular inflammatory conditions 有权

    公开(公告)号：US11311510B2

    公开(公告)日：2022-04-26

    申请号：US16789793

    申请日：2020-02-13

    申请人： Johnson & Johnson Vision Care, Inc.

    发明人： Annabelle Gallois-Bernos

    IPC分类号： A61K31/232 ,  A61K31/557 ,  A61K31/215 ,  A61K31/5575 ,  A61K31/661 ,  A61K9/00 ,  A61K31/16 ,  A61K31/201 ,  A61K31/202 ,  A61K31/203 ,  A61K31/683 ,  A61K9/08

    摘要： The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a polyol wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. Anti-inflammatory lipid mediators can be selected from the group consisting of polyunsaturated fatty acids (e.g., omega-three and omega-six fatty acids), resolvins or a metabolically stable analog, protectins or a metabolically stable analog, lipoxins or a metabolically stable analog, prostaglandins or a metabolically stable analog, retinoic acids, endocannabinoids, metabolites thereof, and mixtures thereof. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.

    ESTERS FOR TREATMENT OF OCULAR INFLAMMATORY CONDITIONS
    7.
    发明申请
    ESTERS FOR TREATMENT OF OCULAR INFLAMMATORY CONDITIONS 审中-公开

    公开(公告)号：US20200206178A1

    公开(公告)日：2020-07-02

    申请号：US16789793

    申请日：2020-02-13

    申请人： Johnson & Johnson Vision Care, Inc.

    发明人： Annabelle Gallois-Bernos

    IPC分类号： A61K31/232 ,  A61K31/557 ,  A61K31/215 ,  A61K31/5575 ,  A61K31/661 ,  A61K9/00 ,  A61K31/16 ,  A61K31/201 ,  A61K31/202 ,  A61K31/203 ,  A61K31/683

    摘要： The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a polyol wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. Anti-inflammatory lipid mediators can be selected from the group consisting of polyunsaturated fatty acids (e.g., omega-three and omega-six fatty acids), resolvins or a metabolically stable analog, protectins or a metabolically stable analog, lipoxins or a metabolically stable analog, prostaglandins or a metabolically stable analog, retinoic acids, endocannabinoids, metabolites thereof, and mixtures thereof. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.

    ESTERS FOR TREATMENT OF OCULAR INFLAMMATORY CONDITIONS
    10.
    发明申请
    ESTERS FOR TREATMENT OF OCULAR INFLAMMATORY CONDITIONS 审中-公开
    用于治疗眼睛炎症反应的条件

    公开(公告)号：US20140364400A1

    公开(公告)日：2014-12-11

    申请号：US14466137

    申请日：2014-08-22

    申请人： Johnson & Johnson Vision Care, Inc.

    发明人： Annabelle Gallois-Bernos

    IPC分类号： A61K31/232 ,  A61K9/00 ,  A61K31/683 ,  A61K31/5575 ,  A61K31/215

    摘要： The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a polyol wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.

    摘要翻译： 本发明涉及用于治疗干眼症和其它炎性眼部病症的眼用组合物和方法。 特别地，本发明涉及包含酯化的抗炎脂质介体的组合物，其是作为抗炎脂质介体和多元醇的反应产物的抗炎脂质介体的酯，其中大部分 抗炎脂质介体以酯形式存在。 以这种方式，组合物基本上不含酸形式的抗炎脂质介质。 该组合物可以通过制剂，溶液，凝胶，软膏和/或条带和/或隐形眼镜局部递送至眼表面。